Category: Epidarex Portfolio News
Apellis’ CEO, Cedric Francois, outlines the company thoughts regarding the emergence of immunotherapy as a therapeutic approach that focuses on correcting the underlying immune dysregulation rather than addressing the symptoms of a conditions. In particular, the article discusses how the complement system plays a key role…
Brighton, Sussex, February 11th 2015 – ENTERPRISE THERAPEUTICS Ltd, a drug discovery company focused on new therapeutics for respiratory diseases, today announced that it has secured £1.6m ($2.4m) in initial Series-A financing from Epidarex Capital. The proceeds will fund, in parallel, low molecular weight drug…
Crestwood, KY – February 10th 2015 – Apellis Pharmaceuticals, Inc. announced that it has begun the Phase I clinical trial of its drug compound APL-2 in patients suffering from age-related macular degeneration (AMD). The trial, labeled ASAP II, will focus on establishing safety of intravitreal…
By Scott Dance, The Baltimore Sun Within a year and a half of launching as a startup, Harpoon Medical’s heart surgery device could be used on humans for the first time in a matter of weeks. The Kent Island-based company expects doctors in Poland to…
Crestwood, KY – December 2nd 2014 – Apellis Pharmaceuticals, Inc., a leading biotechnology company applying immunotherapy to autoimmune disease, today announced that it has completed a $33M private placement of its Series C Preferred Stock. The financing was led by Morningside Ventures and AJU IB…
EDINBURGH, UK, December 2, 2014 – SIRAKOSS, an innovative medical device company based in Edinburgh and Aberdeen today announced it has secured $4.8m (£3.1m) in Series-A financing from a syndicate of investors led by Epidarex Capital. Synthetic bone grafts are used in trauma, spinal and…
CRESTWOOD, KY November 20, 2014 – Apellis Pharmaceuticals Inc. Complement inhibition is the only mechanism thus far to show reductions in the growth of dry AMD. Potentia was the first company to develop a complement inhibitor for the treatment of AMD. APL-2 has the same…
Bethesda, MD, February 18, 2014 – Epidarex Capital, a leading international early-stage life science venture capital fund, has invested in Confluence Life Sciences Inc., a biotechnology company focused on the rapid discovery and development of drugs to address unmet needs in cancer and chronic inflammatory…